Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 3/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548784 | 0.89 | TRPV1 (0.49) | TRPV1PTGESMEN1KMT2A | |
| SCHEMBL2348373 | 0.85 | KMT2A (0.58) | EPAS1PTGESPTGS1MEN1KMT2A | |
| SCHEMBL14541031 | 0.84 | TRPV1 (0.49) | TRPV1PTGESMEN1KMT2A | |
| SCHEMBL1549504 | 0.83 | TRPV1 (0.50) | TRPV1PTGESMEN1KMT2A | |
| SCHEMBL2342854 | 0.83 | IDH1 (0.45) | PTGES | |
| SCHEMBL2346049 | 0.82 | TRPV1 (0.52) | TRPV1MEN1KMT2A | |
| SCHEMBL1548848 | 0.82 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL2342206 | 0.81 | GRM4 (0.50) | TRPV1PTGESMEN1KMT2A | |
| SCHEMBL2346536 | 0.81 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL2348103 | 0.81 | ALDH1A1 (0.53) | TRPV1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314585-B1 | Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC (JP) | 2012-09-12 | — | — | EP | claimed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | claimed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | TRPV1, TRPV2, TRPA1 | TRPV1 1/4885SCN9A 104/4885RPS6KA3 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.